JAK (Janus kinase) inhibitors in rheumatoid arthritis

IMAGE - JAK inhibitors for RA - for website (HOME PAGE) 300 x 165-01

JAK inhibitors, novel oral medications for rheumatoid arthritis, have shown superiority to standard-of-care treatments and provide rapid onset of pain relief

You will learn:
• Inflammatory pathway targets for the treatment of rheumatoid arthritis
• The mechanism of action of JAK inhibitors
• Clinical attributes of JAK inhibitors
• Current evidence on efficacy, versatility in dosing and treatment switching, and safety and tolerability of JAK inhibitors.

WEBINAR HELD ON 29 MARCH 2022.

ATTENTIONKindly note that if you attended the live webinar, you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record the 1 CPD point from the live webinar, invalidating any additional CPD points from the report. Please note deNovo Medica ensures uploading of your CPD points to the HPCSA: please don’t upload these yourself.

To access this module, please register or login: